-transparent.png){kind=logo}
Of 52 patients receiving a mean dose of 2.5g sulphasalazine/day as maintenance therapy for ulcerative colitis, 35 were found to have one or more drug-induced red cell abnormalities, which were not found in 50 normal controls or in 10 colitics not receiving sulphasalazine. Twenty-three of the treated patients had contracted red cells, an abnormality that is thought to result in mild haemolysis. Red cell contraction was related to the dose of sulphasalazine (P smaller than 0.01), the serum total sulphapyridine level (P smaller than 0.001), and acetylator status. Eleven of the treated patients had a macrocytosis, 21 had elevated levels of methaemoglobin, and one had Heinz bodies. A dose of 1.5 g sulphasalazine/day was not associated with red cell contraction, and is suggested as a safer maintenance dose for the asymptomatic colitic.
R E Pounder, and
E R Craven, and
J S Henthorn, and
J M Bannatyne
January 1979,
Lancet (London, England),
R E Pounder, and
E R Craven, and
J S Henthorn, and
J M Bannatyne
March 1980,
Gut,
R E Pounder, and
E R Craven, and
J S Henthorn, and
J M Bannatyne
May 1995,
European journal of gastroenterology & hepatology,
R E Pounder, and
E R Craven, and
J S Henthorn, and
J M Bannatyne
November 1967,
Drug and therapeutics bulletin,
R E Pounder, and
E R Craven, and
J S Henthorn, and
J M Bannatyne
November 1992,
Gut,
R E Pounder, and
E R Craven, and
J S Henthorn, and
J M Bannatyne
January 1988,
Scandinavian journal of gastroenterology. Supplement,
R E Pounder, and
E R Craven, and
J S Henthorn, and
J M Bannatyne
September 2004,
Zeitschrift fur Gastroenterologie,
R E Pounder, and
E R Craven, and
J S Henthorn, and
J M Bannatyne
July 2016,
Expert opinion on pharmacotherapy,
R E Pounder, and
E R Craven, and
J S Henthorn, and
J M Bannatyne
August 1987,
Gut,
R E Pounder, and
E R Craven, and
J S Henthorn, and
J M Bannatyne
June 1988,
Gut,
